May 7, 2019 08:25 AM EDTUpdated 10:50 AM
People
R&D
Pharma

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

John Carroll

Editor & Founder

Now that Al­ler­gan chief Brent Saun­ders has stared down the ac­tivists — for now, any­way — the com­pa­ny is back with a $2.5 bil­lion write­down for their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times